FIELD: biology.
SUBSTANCE: method of identification of tumours, acquisitive to treatment by a monoclone 2C4 either its functional fragment or a monoclone possessing biological characteristics of a monoclone 2C4 or its functional fragment is described. Reveal presence of albuminous complex HER2/HER3 and/or HER2/HER1 in the sample of a tumour. Then define a tumour sensibility to treatment by the specified antibody or its fragment after detection of presence of a complex.
EFFECT: present invention allows to identify simply a tumour, acquisitive to treatment by an antibody 2C4.
22 cl, 8 dwg, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPY OF MALIGNANT TUMOR, RESISTANT TO PLATINUM-BASED MEDICATIONS | 2005 |
|
RU2403065C2 |
| METHODS OF PREDICTING RESPONSE OF TRIPLE NEGATIVE MAMMARY GLAND CANCER TO THERAPY | 2011 |
|
RU2558931C2 |
| HUMANIZED ANTIBODY THAT SHOWS CAPACITY TO BIND ErbB2 AND BLOCK ACTIVATION OF ErbB2 RECEPTOR BY LIGAND (VARIANTS) AND COMPOSITION FOR USING IN CANCER TREATMENT COMPRISING THIS ANTIBODY | 2000 |
|
RU2270029C2 |
| COMPOSITION OF HER2 ANTIBODIES | 2005 |
|
RU2361880C2 |
| SINGLE-DOMAIN ANTIBODY SPECIFICALLY BINDING HUMAN ERBB3 RECEPTOR, WITHOUT CANONICAL DISULPHIDE BOND | 2018 |
|
RU2721854C1 |
| PHARMACEUTICAL COMPOSITIONS AIMED AT Erb-B1 RECEPTORS | 2003 |
|
RU2354402C2 |
| BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY | 2005 |
|
RU2433831C2 |
| INTRODUCTION OF FIXED DOSES OF HER-ANTIBODIES | 2005 |
|
RU2438705C2 |
| BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES | 2016 |
|
RU2653443C2 |
| SELECTION OF MEDICATIONS FOR LUNG CANCER THERAPY BY MEANS OF ANTIBODY-BASED MATRICES | 2008 |
|
RU2519647C2 |
